Article
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Molecular cancer therapeutics - 1 Feb 2014
Acquaviva Jaime, Smith Donald L, Jimenez John-Paul, Zhang Chaohua, Sequeira Manuel, He Suqin, Sang Jim, Bates Richard C, Proia David A
Abstract excerpt
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat this disease. Selective BRAF(V600E) inhibitors, such as vemurafenib, typically induce initial, profound tumor regressions within this group of patients; however, durable responses have been hampered by the emergence of drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.